异麦芽低聚糖对D-半乳糖致衰老大鼠肠道菌群、血清IgG和肠黏膜sIgA的影响

目的探讨异麦芽低聚糖对D-半乳糖致衰老大鼠肠黏膜功能的影响。方法Wistar大鼠随机分为3组：（1）青年对照组,（2）衰老对照组,（3）衰老观察组（衰老＋异麦芽低聚糖）。采用D-半乳糖造成衰老模型后,应用异麦芽低聚糖灌胃,检测各组肠道菌群、血清IgG和肠黏膜sIgA。结果D-半乳糖致衰老大鼠肠道菌群失调;灌胃异麦芽低聚糖后,衰老大鼠肠道双歧杆菌增加（P〈0．05）,肠杆菌和肠球菌数量减少（P〈0．05）;血清IgG、肠黏膜sIgA含量增加（P〈0．05）。结论异麦芽低聚糖可改善衰老机体肠黏膜功能。     

纳米山药多糖合生元结肠靶向微生态调节剂对菌群失调

摘要：目的 探讨纳米山药多糖双歧杆菌合生元结肠靶向微生态调节剂对菌群失调模型大鼠的免疫因子及SOD（超氧化物歧化酶）、MDA（丙二醛）、NO（一氧化氮）、MPO（髓过氧化物酶）表达的影响。方法 大鼠i.g盐酸林可霉素造成菌群失调伴有免疫缺陷肠炎模型,将大鼠随机分成靶向制剂组、阳性对照组和自然恢复组,紫外分光光度法检测结肠匀浆样本SOD、MDA、NO和MPO含量,微量溶血酶标仪分光光度法测定血清溶血素水平,ELISA法测定IL-1β（白细胞介素-1β）、IL-6（白细胞介素-6）、TNF-α（肿瘤坏死因子-α）、sIgA（分泌型免疫球蛋白A）及GM-CSF（粒细胞集落刺激生物因子）含量。结果 与自然恢复组相比,纳米山药多糖组显著提高大鼠溶血素水平及sIgA、GM-CSF和SOD含量（P<0.05）,明显降低大鼠结肠样本中MDA、NO、MPO的含量（P<0.05）,IL-1β、IL-6和TNF-α在大鼠血清中的表达均有不同程度的下降（P<0.05）,且恢复到正常水平。结论 纳米山药多糖双歧杆菌合生元结肠靶向微生态调节剂能减轻肠道炎症,提高溶血素水平、sIgA和GM-CSF含量,降低IL-1β、IL-6和TNF-α含量,提高机体免疫能力,是理想的中药微生态调节剂。     

纳米山药多糖合生元结肠靶向微生态调节剂对菌群失调大鼠 免疫因子及SOD、MDA、NO、MPO表达的影响

摘要：目的 探讨纳米山药多糖双歧杆菌合生元结肠靶向微生态调节剂对菌群失调模型大鼠的免疫因子及SOD（超氧化物歧化酶）、MDA（丙二醛）、NO（一氧化氮）、MPO（髓过氧化物酶）表达的影响。方法 大鼠i.g盐酸林可霉素造成菌群失调伴有免疫缺陷肠炎模型,将大鼠随机分成靶向制剂组、阳性对照组和自然恢复组,紫外分光光度法检测结肠匀浆样本SOD、MDA、NO和MPO含量,微量溶血酶标仪分光光度法测定血清溶血素水平,ELISA法测定IL-1β（白细胞介素-1β）、IL-6（白细胞介素-6）、TNF-α（肿瘤坏死因子-α）、sIgA（分泌型免疫球蛋白A）及GM-CSF（粒细胞集落刺激生物因子）含量。结果 与自然恢复组相比,纳米山药多糖组显著提高大鼠溶血素水平及sIgA、GM-CSF和SOD含量（P<0.05）,明显降低大鼠结肠样本中MDA、NO、MPO的含量（P<0.05）,IL-1β、IL-6和TNF-α在大鼠血清中的表达均有不同程度的下降（P<0.05）,且恢复到正常水平。结论 纳米山药多糖双歧杆菌合生元结肠靶向微生态调节剂能减轻肠道炎症,提高溶血素水平、sIgA和GM-CSF含量,降低IL-1β、IL-6和TNF-α含量,提高机体免疫能力,是理想的中药微生态调节剂。     

双歧杆菌四联活菌片对肝硬化腹泻患者肠道sIgA水平和细胞免疫功能的影响及疗效观察

目的探讨双歧杆菌四联活菌片对肝硬化腹泻患者肠道sIgA水平和细胞免疫功能的影响及疗效观察。方法选择肝硬化腹泻患者90例,随机分为对照组和观察组。两组患者均予以低盐饮食、保肝利尿和纠正水电解质紊乱等治疗。观察组加用双歧杆菌四联活菌片1.5 g,3次/d,连用6周。观察两组患者治疗前后肠道sIgA水平和细胞免疫功能的变化,并比较其临床疗效。结果治疗6周后,两组患者肠道sIgA水平较前明显上升（P〈0.05或P〈0.01）,且观察组上升比对照组更明显（P〈0.05）;观察组CD4＋水平及CD4＋/CD8＋比值较前明显上升（P〈0.05）,CD8＋水平较前变化不明显（P〉0.05）,而对照组治疗前后CD4＋、CD8＋和CD4＋/CD8＋比值无明显改变（P〉0.05）;同时观察组患者的临床总有效率为93.33%,明显高于对照组的73.33%（χ2=6.48,P〈0.05）。结论双歧杆菌四联活菌片治疗肝硬化腹泻具有较好疗效,能提高肠道sIgA水平和纠正外周血T淋巴细胞亚群紊乱,从而增强肠道局部黏膜防御力和机体细胞免疫功能。     

双歧杆菌对新生大鼠坏死性小肠结肠炎肠损伤及肠道菌群影响

目的建立新生SD大鼠坏死性小肠结肠炎（NEC）模型,探讨添加双歧杆菌对新生大鼠NEC模型肠损伤的保护作用及肠道菌群的影响,为应用双歧杆菌防治NEC提供依据：方法SD新生大鼠出生48h开始给予鼠配方奶人工喂养,100％氮气缺氧90s,4℃冷刺激10min,每天2次,连续3d,建立新生SD大鼠NEC模型。按析因设计,32只新生SD大鼠随机分成4组,每组动物各8只。A组为NEC模型组并在出生48h起每日给予长双歧杆菌灌胃（1×10^8CFU／d）;B组为NEC模型组,C组为对照组,都未添加双歧杆菌;D组为对照组并给予长双歧杆菌灌胃（1×10^8CFU／d）。在最后一次缺氧、冷刺激后24h空腹断头处死大鼠,留取回盲部近端肠管组织进行肠组织损伤评分,组织学评分≥2确定为NEC;实验前后留取各组新生鼠粪便,按照张秀荣方法进行肠道菌群检测。应用Kruskal-Wallis H检验等方法进行统计学分析,α=0．05为显著性检验标准。结果开始造模后,A、B组新生SD大鼠相继出现腹泻、腹胀、萎靡、活动减少,A组程度较轻。A、B、C和D组肠组织损伤评分（^-x±s）分别为1．88±0.84、3．13±0．84、0．63±0．52、0．50±0.54,各组间肠组织损伤评分差异有显著性,与B组相比,A组肠组织损伤评分明显降低,但仍高于C、D两组,差异均有显著性。各组实验前肠道细菌总数,杆菌、球菌数,G^＋杆菌、G^＋球菌数差异均无显著性,肠道菌群中杆球菌比值在正常范围中。实验结束时,各组间新生鼠肠道细菌总数,杆菌、球菌数,杆球菌比值,G^＋杆菌、G^＋球菌数及其占肠道总菌群数的比率差异均有显著性;除B组杆菌数外,与实验前相比,各组新生大鼠实验结束后肠道细菌总数、球菌数、杆菌数、G^＋杆菌数、G^＋球菌数均有显著增加,差异均有显著性;A、B组肠道杆球菌比值和G^＋杆菌数占肠道总菌群数比     

旋毛虫感染小鼠肠道菌群变化的研究

目的通过观察黑龙江株旋毛虫感染小鼠肠道分泌物中分泌型免疫球蛋白A、肠道菌群的变化,探讨感染小鼠肠道菌群的变化。方法分别于小鼠感染黑龙江株旋毛虫后7、14、21、28和35d,观察模型组及对照组小鼠肠道分泌物中的分泌型免疫球蛋白A、肠道双歧杆菌、乳酸杆菌、肠杆菌、肠球菌的菌群变化。sIgA采用放射免疫法检测。结果模型组sIgA分泌水平在感染后14d达高峰,随后缓慢下降但始终保持高水平（P〈0．01）。模型组肠道双歧杆菌的数量在感染后7d略低于对照组（P〈0．05）,第14天降至最低水平,随后逐渐升高,至感染后35d恢复正常水平。乳酸杆菌的数量在感染后7d略低于对照组,第14天降至最低水平,随后逐渐增加（P〈0．05）。肠杆菌的数量在感染后7d略高于对照组,感染后14d明显高于对照组,随后始终保持下降趋势（P〈0．05）。肠球菌在感染后7d略高于对照组（P〈0．05）,在14d明显高于对照组,随后缓慢下降,至感染后35d恢复正常水平。结论旋毛虫感染小鼠sIga的分泌在肠道免疫中发挥重要作用,同时也影响肠道菌群;肠道菌群的变化可能与旋毛虫感染小鼠免疫系统中sIgA的分泌有关。     

婴儿双歧杆菌对花生过敏小鼠模型肠道Th2反应的调节

目的研究婴儿型双歧杆菌对花生过敏小鼠肠道Th2型反应的调节作用。方法通过应用花生蛋白诱导肠道的Th2型反应,建立食物过敏小鼠模型。过敏小鼠灌胃给予婴儿型双歧杆菌（ATCC菌或CGMCC0313-2）或不做处理。然后分离小鼠小肠黏膜CD4＋T细胞或DC,另取肠黏膜组织进行石蜡包埋甲苯胺蓝染色肥大细胞计数,HE染色进行嗜酸细胞和单个核细胞计数,流式细胞检测CD4＋T中Th2（CD4＋IL4＋T）细胞和Treg（CD4＋CD25＋Foxp3＋T）比例,另取CD4＋T进行CFSE标记,与DC共培养4d后流式细胞检测CD4＋T增殖反应,收集细胞培养液ELISA检测IL-4、IL-5和IL—13分泌水平。结果过敏组小鼠Th2型细胞数,CD4＋T细胞增殖反应,IL4、IL-5和IL-13水平,肠黏膜中肥大细胞、嗜酸性细胞和单个核细胞数均明显高于对照组（P〈0．01）,而Treg数目低于对照组（P〈0．01）,婴儿双歧杆菌干预后,婴儿双歧杆菌组Th2型细胞数,IL4、IL-5和IL-13水平,肠黏膜中肥大细胞、嗜酸性细胞和单个核细胞数均明显低于过敏组（P〈0．01）,而Treg数目高于过敏组（P〈0．01）。结论口服婴儿型双歧杆菌可以抑制花生过敏导致的肠道Th2型反应。     

双歧杆菌对溃疡性结肠炎小鼠外周血和肠系膜淋巴结CD4~＋ CD25~＋ Foxp3~＋调节T细胞表达的影响

目的探讨双歧杆菌治疗溃疡性结肠炎与CD4＋ CD25＋ Foxp3＋调节T细胞的相关可能机制。方法采用DSS制作UC小鼠结肠炎模型,随机分成3组：正常对照（NC）组,模型（MD）组,双歧杆菌治疗（BbT）组。造模7 d后,给予双歧杆菌后续治疗7 d。评估小鼠疾病活动指数（DAI）,结肠行HE染色及病理学评分（HDS）;流式细胞仪检测外周血和肠系膜淋巴细胞中表达CD4＋ CD25＋ Foxp3＋的Treg细胞的百分比率。结果 BbT组的DAI明显低于模型组（P〈0.05）;MD组HDS明显高于正常组（P〈0.05）;BbT组的HDS明显低于模型组（P〈0.05）;模型组外周血和肠系膜淋巴细胞CD4＋ CD25＋ Foxp3＋Treg细胞占CD4＋T细胞的百分率明显低于正常组（P〈0.05）;BbT组结肠外周血和肠系膜淋巴细胞CD4＋ CD25＋ Foxp3＋Treg细胞占CD4＋T细胞的百分率明显高于模型组（P〈0.05）。结论双歧杆菌可以提高CD4＋ CD25＋ Foxp3＋Treg数量,调节机体和肠道免疫功能,对UC发挥了一定的治疗作用。     

双歧杆菌对肠上皮细胞生长和白介素-8分泌功能的影响

目的探讨双歧杆菌对人肠上皮细胞株HT29生长及其IL-8分泌水平的影响。方法HT29细胞在96孔板上生长24h后分为正常细胞对照组、高剂量双歧杆菌共培养组（细菌终浓度为1×10^10CFU／m1）、低剂量双歧杆菌共培养组（细菌终浓度为1×10^6CFU／ml）、轮状病毒感染对照组,分别加入不同剂量双歧杆菌和感染轮状病毒共培养,继续培养24h,光镜下观察细胞生长状态,MTT比色法检测细胞活性情况,ELISA检测细胞培养上清中IL-8表达水平。结果光镜下观察到双歧杆菌与HT29细胞共培养后细胞形态无明显改变,共培养24h后MTT检测双歧杆菌对HT29细胞增殖和调亡无明显影响,但轮状病毒感染对照组细胞病变脱落,活细胞数量明显减少。共培养6h,其余3组细胞培养上清中IL-8分泌较正常细胞对照组增加（P〈0．05）,高剂量双歧杆菌组增加较低剂量双歧杆菌组差异有显著性（P〈0．05）,但两个剂量组均明显低于轮状病毒感染阳性对照组的IL-8分泌增加水平（P〈0．05）;感染后24h,细胞培养上清中IL-8分泌水平高于正常细胞对照组（P〈0．05）,但高、低剂量双歧杆菌组之间差异无显著性（P〉0．05）,两个剂量组IL-8分泌增加水平均明显低于轮状病毒感染阳性对照组（P〈0．01）。结论两歧双歧杆菌共培养不影响HT29细胞的生长,双歧杆菌能够促进HT29细胞分泌细胞因子IL-8,但明显低于致病微生物刺激引起的细胞因子分泌水平改变,这种促进作用无时间-剂量依赖关系,提示双歧杆菌与肠道内致病微生物对肠道免疫功能的影响不同,双歧杆菌促进肠上皮细胞分泌IL-8可能与其参与的肠道黏膜免疫系统发育成熟相关。     

胆管结扎对大鼠肠道双歧杆菌组成的影响

目的分析胆管结扎对SD大鼠肠道双歧杆菌菌群结构组成的影响。方法采集手术前3 d和手术后2周5只模型组和5只对照组大鼠的粪便样品,提取粪便样品中微生物的混合DNA进行双歧杆菌类群特异性PCR-DGGE,结合主成分分析技术比较2组大鼠在手术前后肠道内双歧杆菌结构组成的变化。结果DGGE图谱及其主成分分析表明手术后对照组和模型组大鼠肠道双歧杆菌菌群的结构组成明显不同,主要表现在假长双歧杆菌的数量在模型组显著增加,而动物双歧杆菌却明显减少。结论胆管结扎导致SD大鼠肠道双歧杆菌结构发生异常变化。     

Enhancement of ovalbumin-specific IgA responses via oral boosting with antigen co-administered with an aqueous Solanum torvum extract

An experiment was conducted with the objective to enhance mucosal immunity against ovalbumin (OVA) by co-administration of OVA with an aqueous extract from the fruit of Solanum torvum (STE). Five groups of female ICR mice aged approximately 8 weeks at the commencement of the experiment were caged in groups of eight and received various treatments. The treatments included OVA alone, OVA with cholera toxin (CT), and OVA with various doses of STE. Mice were primed intraperitoneally with 500 microg of OVA alone or co-administered with 0.1 microg CT, or with 1 microg STE. All mice were boosted orally via gastric intubation 14 days after priming with 10 mg OVA alone, or co-administered with 10 microg CT or with 10 mg, 1 mg or 0.1 mg STE. One week later all mice were killed and organs obtained for analysis of the immune response. Intestinal, faecal and pulmonary OVA-specific sIgA concentration was significantly increased (p<0.05) in mice that received booster combinations of OVA/CT and OVA with all extract doses (p<0.05). Specific serum IgG titres did not differ significantly between groups. It is concluded that STE can significantly enhance secretory immunity in the intestine to OVA with mucosal homing to the lungs. The adjuvant effect of STE is comparable to that of CT.     

Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector

Many infectious agents infiltrate the host at the mucosal surfaces and then spread systemically. This implies that an ideal vaccine should induce protective immune responses both at systemic and mucosal sites to counteract invasive mucosal pathogens. We evaluated the in vivo systemic and mucosal antigen-specific immune response induced in mice by intramuscular administration of an integrase defective lentiviral vector (IDLV) carrying the ovalbumin (OVA) transgene as a model antigen (IDLV-OVA), either alone or in combination with sublingual adjuvanted OVA protein. Mice immunized intramuscularly with OVA and adjuvant were compared with IDLV-OVA immunization. Mice sublingually immunized only with OVA and adjuvant were used as a positive control of mucosal responses. A single intramuscular dose of IDLV-OVA induced functional antigen-specific CD8+ T cell responses in spleen, draining and distal lymph nodes and, importantly, in the lamina propria of the large intestine. These results were similar to those obtained in a prime-boost regimen including one IDLV immunization and two mucosal boosts with adjuvanted OVA or vice versa. Remarkably, only in groups vaccinated with IDLV-OVA, either alone or in prime-boost regimens, the mucosal CD8+ T cell response persisted up to several months from immunization. Importantly, following IDLV-OVA immunization, the mucosal boost with protein greatly increased the plasma IgG response and induced mucosal antigen-specific IgA in saliva and vaginal washes. Overall, intramuscular administration of IDLV followed by protein boosts using the sublingual route induced strong, persistent and complementary systemic and mucosal immune responses, and represents an appealing prime-boost strategy for immunization including IDLV as a delivery system.     

Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice

A critical element in improving the potency of cancer vaccines, especially pure protein or peptide antigens, is to develop procedures that can strongly but safely increase their ability to induce immune responses. Here, we describe that encapsulation of a pure protein antigen and interleukin-2 (IL-2) together into liposomes significantly improves immune responses and tumor protection. Groups of C57Bl/6 mice were immunized weekly ×4 with –0.1 mg of ovalbumin (OVA) injected subcutaneously in PBS or encapsulated in liposomes with or without human recombinant IL-2. Control groups included mice immunized to irradiated E.G7-OVA cells (that express ovalbumin), or to PBS. Sera were collected and pooled by immunization group at baseline and at weeks 2 and 4 to measure antibody responses to OVA by ELISA. Splenocytes obtained at week 4 were tested for anti-OVA cellular responses by ELISPOT. Mice were then challenged to a lethal dose of E.G7-OVA cells to measure tumor-protective immunity. IL-2 liposomes caused no detectable toxicity. Antibody, CD8⁺ T cell, and tumor-protective immune responses were markedly enhanced in mice immunized to OVA + IL-2 in liposomes compared to mice immunized to OVA, either alone or encapsulated into liposomes without IL-2. These results indicate that IL-2 liposomes enhance antibody, cellular, and tumor-protective immune responses to immunization with a soluble protein. This may provide a simple, safe, and effective way to enhance the immunogenicity of vaccines that consist of pure protein antigens. Supported by grant CA096804 (DJ)     

Immunological Adjuvant Effect of a Water‐Soluble Polysaccharide,CPP, from the Roots of Codonopsis pilosula on the Immune Responses to Ovalbumin in Mice

In this study, one water‐soluble polysaccharide, CPP, was purified from the root of Codonopsis pilosula. The immunomodulatory effect and the adjuvant potential of CPP on the cellular and humoral immune response of ICR mice against ovalbumin (OVA) were investigated. CPP was shown not to be lethal in vivo for mice in doses ranging from 0.5 to 4 mg. ICR Mice were immunized subcutaneously with 0.1 mg of OVA alone or with 0.1 mg of OVA dissolved in saline‐containing aluminum hydroxide gel (Alum) (0.2 mg), QuilA (0.01 and 0.02 mg) or CPP (0.5, 1 or 2 mg) on days 1 and 15. Two weeks later (day 28), concanavalin A (ConA)‐, lipopolysaccharide (LPS)‐, and OVA‐stimulated splenocyte proliferation, and OVA‐specific serum antibodies were measured. CPP significantly enhanced the ConA‐, LPS‐, or OVA‐induced splenocyte proliferation in the OVA‐immunized mice especially at a dose of 1 mg (P<0.05 or P<0.01). The OVA‐specific IgG, IgG1, and IgG2b antibody levels in serum were also significantly enhanced by CPP compared with OVA control group (P<0.05 or P<0.01). The results suggest that CPP could be a safe efficacious adjuvant for use in vaccines against both pathogens and cancer.     

Effect of respiratory syncytial virus infection on the uptake of and immune response to other inhaled antigens

Groups of BALB/c mice were sham infected or inoculated intranasally (IN) with live RSV. From Day 4 to 8 after infection, the animals were exposed IN to ovalbumin (OVA) with or without alum adjuvant. At different intervals, levels of OVA concentration in serum, IgG-anti-OVA antibody activity in serum, and IgA-anti-OVA antibody activity in bronchial washings were determined, employing the ELISA technique. IgE-anti-OVA antibody titers in serum and bronchial washings were assessed by PCA. OVA concentrations in serum were significantly higher in RSV-infected animals compared to uninfected controls. The use of alum adjuvant also increased OVA uptake in uninfected animals but to a lesser extent than RSV infection. RSV-infected animals developed significantly higher OVA-specific antibody titers of IgG isotype in serum and IgA isotype in bronchial washings than the uninfected controls, while alum enhanced the immune response less markedly but still significantly in uninfected mice. An IgE antibody response to OVA in serum was demonstrable in 50% of RSV-infected mice immunized IN with OVA and alum, while all uninfected animals and RSV-infected animals immunized with OVA alone (without adjuvant) failed to develop a detectable IgE response. These findings suggest that infections with viral agents such as RSV may function as adjuvants for other antigens inhaled during acute respiratory infection. These observations may explain the alterations in the immune response to other antigens in patients with acute viral-induced bronchopulmonary diseases.     

Effect of Liposomal Formulations and Immunostimulating Peptidoglycan Monomer (PGM) on the Immune Reaction to Ovalbumin in Mice

The adjuvant activity of liposomes and immunostimulating peptidoglycan monomer (PGM) in different formulations has been studied in mice model using ovalbumin (OVA) as an antigen. PGM is a natural compound of bacterial origin with well-defined chemical structure: GlcNAc-MurNAc-l-Ala-d-isoGln-mesoDpm(εNH₂)-d-Ala-d-Ala. It is a non-toxic, non-pyrogenic, and water-soluble immunostimulator. The aim of this study was to investigate the influence of different liposomal formulations of OVA, with or without PGM, on the production of total IgG, as well as of IgG1 and IgG2a subclasses of OVA-specific antibodies (as indicators of Th2 and Th1 type of immune response, respectively). CBA mice were immunized s.c. with OVA mixed with liposomes, OVA with PGM mixed with liposomes, OVA encapsulated into liposomes and OVA with PGM encapsulated into liposomes. Control groups were OVA in saline, OVA with PGM in saline, and OVA in CFA/IFA adjuvant formulation. The entrapment efficacy of OVA was monitored by HPLC method. The adjuvant activity of the mixture of OVA and empty liposomes, the mixture of OVA, PGM, and liposomes and PGM encapsulated with OVA into liposomes on production of total anti-OVA IgG was demonstrated. The mixture of PGM and liposomes exhibited additive immunostimulating effect on the production of antigen-specific IgGs. The analysis of IgG subclasses revealed that encapsulation of OVA into liposomes favors the stimulation of IgG2a antibodies, indicating the switch toward the Th1 type of immune response. When encapsulated into liposomes or mixed with liposomes, PGM induced a switch from Th1 to Th2 type of immune response. It could be concluded that appropriate formulations of antigen, PGM, and liposomes differently affect the humoral immune response and direct the switch in the type of immune response (Th1/Th2).     

Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice

The adjuvant activity of liposomes and immunostimulating peptidoglycan monomer (PGM) in different formulations has been studied in mice model using ovalbumin (OVA) as an antigen. PGM is a natural compound of bacterial origin with well-defined chemical structure: GlcNAc-MurNAc-L-Ala-D-isoGln-mesoDpm(epsilonNH2)-D-Ala-D-Ala. It is a non-toxic, non-pyrogenic, and water-soluble immunostimulator. The aim of this study was to investigate the influence of different liposomal formulations of OVA, with or without PGM, on the production of total IgG, as well as of IgG1 and IgG2a subclasses of OVA-specific antibodies (as indicators of Th2 and Th1 type of immune response, respectively). CBA mice were immunized s.c. with OVA mixed with liposomes, OVA with PGM mixed with liposomes, OVA encapsulated into liposomes and OVA with PGM encapsulated into liposomes. Control groups were OVA in saline, OVA with PGM in saline, and OVA in CFA/IFA adjuvant formulation. The entrapment efficacy of OVA was monitored by HPLC method. The adjuvant activity of the mixture of OVA and empty liposomes, the mixture of OVA, PGM, and liposomes and PGM encapsulated with OVA into liposomes on production of total anti-OVA IgG was demonstrated. The mixture of PGM and liposomes exhibited additive immunostimulating effect on the production of antigen-specific IgGs. The analysis of IgG subclasses revealed that encapsulation of OVA into liposomes favors the stimulation of IgG2a antibodies, indicating the switch toward the Th1 type of immune response. When encapsulated into liposomes or mixed with liposomes, PGM induced a switch from Th1 to Th2 type of immune response. It could be concluded that appropriate formulations of antigen, PGM, and liposomes differently affect the humoral immune response and direct the switch in the type of immune response (Th1/Th2).     

流感新型黏膜疫苗的研究

目的评价PorA、PorB和Class4对流感裂解疫苗的免疫增强作用,从中挑选出最有效的流感黏膜佐剂,为发展流感黏膜疫苗提供理论基础。方法流感三价裂解抗原按比例与PorA、PorB和Class4非共价结合,滴鼻免疫Balb／c小鼠3次,采取间接ELISA检测血清特异性IgG抗体及抗体亚型,检测鼻咽、肺、小肠和阴道冲洗液中IgA效价,采用血凝抑制试验检测血清中HAI效价。结果PorB重组蛋白佐剂组较无佐剂的流感裂解抗原组在提高小鼠早期免疫应答的同时诱导较强的系统免疫应答和黏膜免疫应答;PorA组也有黏膜佐剂的功能,但和无佐剂的流感裂解抗原组相比,差异无统计学意义。结论在蛋白体的三分子中,以PorB为佐剂的流感黏膜疫苗不仅提高了抗原的系统免疫应答,而且诱导了较强的小鼠呼吸道、生殖道的局部黏膜免疫应答,为流感黏膜疫苗的研制奠定了理论基础。     

TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines

Cancer vaccines, while theoretically attractive, present difficult challenges that must be overcome to be effective. Cancer vaccines are often poorly immunogenic and may require augmentation of immunogenicity through the use of adjuvants and/or immune response modifiers. Toll-like receptor (TLR) ligands are a relatively new class of immune response modifiers that may have great potential in inducing and augmenting both cellular and humoral immunity to vaccines. TLR7 ligands produce strong cellular responses and specific IgG2a and IgG2b antibody responses to protein immunogens. This study shows that a new TLR7 ligand, 3M-019, in combination with liposomes produces very strong immune responses to a pure protein prototype vaccine in mice. Female C57BL/6 mice were immunized subcutaneously with ovalbumin (OVA, 0.1 mg/dose) weekly 4x. Some groups were immunized to OVA plus 3M-019 or to OVA plus 3M-019 encapsulated in liposomes. Both antibody and cellular immune responses against OVA were measured after either two or four immunizations. Anti-OVA IgG antibody responses were significantly increased after two immunizations and were substantially higher after four immunizations in mice immunized with OVA combined with 3M-019. Encapsulation in liposomes further augmented antibody responses. IgM responses, on the other hand, were lowered by 3M-019. OVA-specific IgG2a levels were increased 625-fold by 3M-019 in liposomes compared to OVA alone, while anti-OVA IgG2b levels were over 3,000 times higher. In both cases encapsulation of 3M-019 in liposomes was stronger than either liposomes alone or 3M-019 without liposomes. Cellular immune responses were likewise increased by 3M-019 but further enhanced when it was encapsulated in liposomes. The lack of toxicity also indicates that this combination may by safe, effective method to boost immune response to cancer vaccines.     

双歧醋对高脂饮食大鼠血脂的影响

目的 探讨双歧醋对高脂饮食大鼠血脂的影响作用.方法 48只SD大鼠被随机分成双歧醋低剂量组[1.8 mL/( kg·BW)]、中剂量组[3.4 mL/(kg · BW)]、高剂量组[6.8 mL/(kg · BW)]和市售醋组[3.4 mL/( kg·BW)]、高脂模型组以及正常组,观察双歧醋对高脂饮食大鼠血脂的影响作用,测定指标包括大鼠体重、肝指数、体脂指数、病理学观察肝脏脂肪变性等.结果 实验结果显示,双歧醋各组所有测定指标值都较高脂模型组有明显好转,特别是甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)水平双歧杆菌醋的高、中量组与市售醋组比较差异有统计学意义(P＜0.05).结论 双歧醋能有效预防高脂饮食大鼠的血脂水平升高,对预防体重、肝指数升高和肝脏脂肪变性也有一定作用.